Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Sinopharm Group Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Sinopharm Group şirketinin toplam hissedar öz sermayesi CN¥122.4B ve toplam borcu CN¥95.6B olup, bu da borç-öz sermaye oranını 78.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥429.6B ve CN¥307.2B dir. Sinopharm Group 'in FAVÖK'ü CN¥20.9B faiz karşılama oranı 11.4 dur. Şirketin CN¥43.3B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.
Anahtar bilgiler
78.1%
Borç/özkaynak oranı
CN¥95.61b
Borç
| Faiz karşılama oranı | 11.4x |
| Nakit | CN¥43.33b |
| Eşitlik | CN¥122.43b |
| Toplam yükümlülükler | CN¥307.15b |
| Toplam varlıklar | CN¥429.58b |
Son finansal sağlık güncellemeleri
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23
Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Recent updates
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet
Jul 27Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956
Jun 16Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?
May 13Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?
Jan 31Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
Dec 31Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)
Nov 29If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity
Nov 14Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?
Nov 01Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?
Sep 20Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Aug 18Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?
Aug 02Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
Apr 26These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jul 31Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Jul 10Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement
Jun 05We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Apr 11A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Mar 21Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns
Mar 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jan 09Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price
Dec 19Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Dec 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Sep 23A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Sep 10Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Aug 28Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Jun 13Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Jun 06Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value
May 24Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
May 11Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?
Mar 20We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt
Mar 05You Have To Love Sinopharm Group Co., Ltd.'s (HKG:1099) Dividend
Feb 18
Should You Be Impressed By Sinopharm Group's (HKG:1099) Returns on Capital?
Feb 03Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 1099 'nin kısa vadeli varlıkları ( CN¥382.4B ) kısa vadeli yükümlülüklerini ( CN¥283.2B ) aşıyor.
Uzun Vadeli Yükümlülükler: 1099 şirketinin kısa vadeli varlıkları ( CN¥382.4B ) uzun vadeli yükümlülüklerini ( CN¥23.9B ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 1099 'nin net borç/öz sermaye oranı ( 42.7% ) yüksek olarak değerlendiriliyor.
Borcun Azaltılması: 1099 'nin borç/öz sermaye oranı son 5 yılda 97.2% seviyesinden 78.1% seviyesine düştü.
Borç Kapsamı: 1099 'nin borcu işletme nakit akışı ( 20.4% ) tarafından iyi bir şekilde karşılanmaktadır.
Faiz Kapsamı: 1099 'in borcuna ilişkin faiz ödemeleri EBIT ( 11.4 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.